CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Tapestry Pharmaceuticals, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Tapestry Pharmaceuticals, Inc.
2310 S.E. Delaware Avenue
Suite G281
Ankeny, IA  50021  United States Ticker: TPPHQTPPHQ
This company is no longer actively traded on any major stock exchange.
Business Summary
Tapestry Pharmaceuticals, Inc. (Tapestry) is a pharmaceutical company focused on the development of therapies for the treatment of cancer. The Company is also engaged in evaluating new therapeutic agents and/or related technologies. During the fiscal year ended December 31, 2006 (fiscal 2006), all of its products and technologies are in the early stages of development. It commenced Phase I clinical trials of TPI 287, its third generation taxane, in May 2005 with an every seven day dosing (Q7D) study, and in January 2006, it commenced a second Phase I study with an alternative every three week dosing (Q21D) regimen. The focus of its business was the production and sale of paclitaxel, a naturally occurring chemotherapeutic anti-cancer agent. In January 2006, the Company discontinued its research activities relating to the Huntington’s Disease program and discontinued its development activities on TPI 284, its peptide linked cytotoxic compound.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/26/200712/27/2006YesYes---

Industries
SIC Code Description
2833 Medicinal chemicals and botanical products
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Leonard P.Shaykin 63 4/4/2008 6/1/1993
Chief Executive Officer, Chief Financial Officer, Director Gordon H.Link 56 4/4/2008 9/1/1993
Chief Operating Officer, Senior Vice President Martin M.Batt 64 4/1/2005 1/1/2002
6 additional Officers and Directors records available in full report.

Business Names
Business Name
NaPro BioTherapeutics, Ltd.
NBT, Ltd.
Tapestry Pharmaceuticals, Inc.
TPPHQ

General Information
Number of Employees: 32 (As of 12/27/2006)
Outstanding Shares: 16,629,861 (As of 11/1/2007)
Shareholders: 350
Stock Exchange: OTC
Federal Tax Id: 841187753


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023